StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.92−0.81 (-1.85%)

Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –

Rigel Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Rigel Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $276.79M, up 3.3% year over year. For fiscal 2025 it was $294.28M, up 64.1% from the year before. The highest annual figure on record is $294.28M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$294.28M+64.1%
FY2024Dec 31, 2024$179.28M+53.4%
FY2023Dec 31, 2023$116.88M-2.8%
FY2022Dec 31, 2022$120.24M-19.4%
FY2021Dec 31, 2021$149.24M+37.4%
FY2020Dec 31, 2020$108.62M+83.2%
FY2019Dec 31, 2019$59.29M+33.2%
FY2018Dec 31, 2018$44.51M+892.6%
FY2017Dec 31, 2017$4.48M-78.0%
FY2016Dec 31, 2016$20.38M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$78.70M-22.6%
Q1 FY2026Mar 31, 2026$58.82M+10.3%
Q4 FY2025Dec 31, 2025$69.80M+21.2%
Q3 FY2025Sep 30, 2025$69.46M+25.6%
Q2 FY2025Jun 30, 2025$101.69M+176.0%
Q1 FY2025Mar 31, 2025$53.33M+80.6%
Q4 FY2024Dec 31, 2024$57.60M+60.9%
Q3 FY2024Sep 30, 2024$55.31M+96.6%
Q2 FY2024Jun 30, 2024$36.84M+37.0%
Q1 FY2024Mar 31, 2024$29.53M+13.3%
Q4 FY2023Dec 31, 2023$35.79M-30.2%
Q3 FY2023Sep 30, 2023$28.13M+25.5%
Q2 FY2023Jun 30, 2023$26.89M-9.8%
Q1 FY2023Mar 31, 2023$26.07M+55.8%
Q4 FY2022Dec 31, 2022$51.28M+151.3%
Q3 FY2022Sep 30, 2022$22.41M+4.0%
Q2 FY2022Jun 30, 2022$29.82M+13.5%
Q1 FY2022Mar 31, 2022$16.74M-79.3%
Q4 FY2021Dec 31, 2021$20.41M+10.6%
Q3 FY2021Sep 30, 2021$21.54M+17.2%
Q2 FY2021Jun 30, 2021$26.27M+63.9%
Q1 FY2021Mar 31, 2021$81.02M+45.3%
Q4 FY2020Dec 31, 2020$18.45M+19.8%
Q3 FY2020Sep 30, 2020$18.39M-11.8%
Q2 FY2020Jun 30, 2020$16.02M+53.9%
Q1 FY2020Mar 31, 2020$55.76M+341.7%
Q4 FY2019Dec 31, 2019$15.40M-59.3%
Q3 FY2019Sep 30, 2019$20.86M+328.7%
Q2 FY2019Jun 30, 2019$10.41M+482.4%
Q1 FY2019Mar 31, 2019$12.62M–
Q4 FY2018Dec 31, 2018$37.86M+4106.3%
Q3 FY2018Sep 30, 2018$4.87M–
Q2 FY2018Jun 30, 2018$1.79M-50.1%
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$900.00K–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$3.58M–

More Rigel Pharmaceuticals figures

See a number that looks wrong?